Active Ingredient(s): Ravulizumab-cwvz
FDA Approved: * December 21, 2018
Pharm Company: * ALEXION PHARM

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Ultomiris Overview

Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).[3][2] Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tis...

Read more Ultomiris Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ravulizumab

Recent Ultomiris Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 300mg/30ml(10mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ultomiris: (3 results)

Sorted by National Drug Code
  • 25682-022 Ultomiris 300 mg/30ml Intravenous Solution, Concentrate by Alexion Pharmaceuticals Inc.
  • 25682-025 Ultomiris 300 mg/3ml Intravenous Solution, Concentrate by Alexion Pharmaceuticals Inc.
  • 25682-028 Ultomiris 1100 mg/11ml Intravenous Solution, Concentrate by Alexion Pharmaceuticals Inc.

Other drugs which contain Ravulizumab-cwvz or a similar ingredient: (1 result)